2007
DOI: 10.1016/s1474-4422(07)70108-4
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

11
294
2
18

Year Published

2008
2008
2020
2020

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 359 publications
(325 citation statements)
references
References 27 publications
11
294
2
18
Order By: Relevance
“…65 This study was a shorter, 16-week maintenance phase. The maximum dose was 16 mg/24 hours for rotigotine and 4.5 mg/day for pramipexole.…”
Section: Phase III Clinical Trial Results In Advanced Patientsmentioning
confidence: 99%
“…65 This study was a shorter, 16-week maintenance phase. The maximum dose was 16 mg/24 hours for rotigotine and 4.5 mg/day for pramipexole.…”
Section: Phase III Clinical Trial Results In Advanced Patientsmentioning
confidence: 99%
“…In another trial using similarly selected advanced PD patients, transdermal rotigotine and oral pramipexole arms were studied against placebo. Rotigotine was shown to be noninferior to pramipexole for reduction in daily 'off' time [57]. Both agents increased 'on' time without dyskinesia without increasing 'on' time with dyskinesia.…”
Section: Continuous Transdermal Delivery Of Rotigotinementioning
confidence: 96%
“…Both agents increased 'on' time without dyskinesia without increasing 'on' time with dyskinesia. However, responder rates (proportion of patients with ≥30% reduction in daily 'off' time) were somewhat higher for the pramipexole group [57]. Similarly, in a study comparing rotigotine to ropinirole in early PD, rotigotine was shown to have a less robust symptomatic effect [58], although one cannot be certain of dose equivalency.…”
Section: Continuous Transdermal Delivery Of Rotigotinementioning
confidence: 98%
“…Было показано, что АДР уменьшают длительность «OFF-эпизодов», чему есть доказательства класса I для прамипексола [48,49], ропинирола [50][51][52], ротиготина в трансдермальной фор-ме [53,54], а также апоморфина (подкожные инъекции) [16,53]. По данным разных исследований, добавление АДР к леводопе сокращает «OFF-период» на 15-44% или от 1,5 до 2,8 ч [18,51,53,54,[57][58][59][60][61]. При этом добиться не менее чем 30% сокращения «OFF-периода» можно у боль-шой доли (60-70%) больных [54].…”
unclassified
“…По данным разных исследований, добавление АДР к леводопе сокращает «OFF-период» на 15-44% или от 1,5 до 2,8 ч [18,51,53,54,[57][58][59][60][61]. При этом добиться не менее чем 30% сокращения «OFF-периода» можно у боль-шой доли (60-70%) больных [54]. Есть данные по сопо-ставимому эффекту ротиготина и прамипексола, превос-ходящему эффект плацебо у пациентов, уже получающих леводопу (исследование CLEOPATRA) [54].…”
unclassified